Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLARA: Olaparib and Durvalumab with Radiosurgery for Breast Cancer Brain Metastases
NCT04711824Phase 2Active, not recruiting
- Sponsor
- Colette Shen
- Start
- Mar 2022
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in breast cancer and brain metastases, sponsored by Colette Shen. Primary endpoints: Frequency and severity of adverse events at 4 weeks and Intracranial Disease control rate at 6 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT04711824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711824.